Checkpoint Therapeutics Inc expected to post a loss of 14  cents a share - Earnings Preview

Checkpoint Therapeutics

02/05/2022 14:11

* Checkpoint Therapeutics Inc  CKPT.OQ   CKPT.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 4 (estimated). 
    * The New York City-based  company is expected to report  a
74.3% decrease in revenue to $17.5 thousand from $68 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Checkpoint
Therapeutics
Inc is for a loss of 14 cents per share. For the same quarter
last year, the company reported a loss of 9 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $20​, above​ its last closing price
of $1.26. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.15       -0.15      -0.39     Missed  -153.2
 Sep. 30 2021  -0.13       -0.14      -0.14     Met     -2.9
 Jun. 30 2021  -0.10       -0.10      -0.12     Missed  -15.4​
 Mar. 31 2021  -0.11       -0.10      -0.09     Beat    14.3
 ​​Dec.        -0.08       -0.08      -0.17     Missed  -112.5
 31 2020                                                
 Sep. 30 2020  -0.08       -0.08      -0.09     Missed  -12.5​
 Jun. 30 2020  -0.09       -0.09      -0.09     Met     0
 Mar. 31 2020  -0.13       -0.13      -0.06     Beat    52.6
 This summary was machine generated May 2 at 13:11 GMT.  All
figures in US dollars  unless otherwise stated